Abstract Body

Background

Background. Progressive Multifocal Leukoencephalopathy (PML) is a severe demyelinating disease caused by JC virus (JCV) reactivation. CSF JCV-DNA level at diagnosis and its variation over time may help predict outcome. The aim was to study plasma JCV-DNA level changes, in addition to CSF, to assess its prognostic potential.

Methods

Methods. We selected cases from the Italian PML Registry (NCT06594614) observed in the period 1996-2025 with ≥2 sequential quantitative JCV-DNA examinations of CSF (n=98) and/or plasma (n=38), with last sample collected 30-90 (±14) days from diagnosis. We assessed, in both CSF and plasma, the best JCV-DNA cutpoint values for predicting 1-year survival at 30, 60 and 90 (± 14) days of follow-up of the following: 1) single point determination (Log c/mL), 2) slope (Log difference at each determination ÷ difference of days between each sample), 3) delta (Log difference between last and first determination). We used nonparametric tests to compare values among the CSF and plasma groups, and the maximized metric method by Youden Index to assess cutpoints, sensitivity and specificity.

Results

Results. There were no significant differences in sex, age and survival days between the CSF and plasma groups. People with HIV were the most represented in both groups, followed by those with hematological malignancies. JCV-DNA level at first assessment was 3.3 c/mL (25th-75thIQR 2.5-4.2) in CSF and 2.0 c/mL (2.0-3.0) in plasma, with detection rates of 80% and 42%, respectively.

Punctual JCV-DNA cutpoints had sensitivity/specificity values for predicting 1-year mortality at 30, 60 and 90 days of 30%/95.5%, 55%/88% and 55.6%/75% in CSF and 72.7%/56.3%, 100%/68.8% and 100%/100% in plasma. 

For CSF, the highest sensitivity/specificity values were observed at 90 days for slope (88.9%/75%) and delta (66.7%/91.7%) and, for plasma, at 60 days for slope (80%/75%) and at 90 days for delta (100%/75%)(Figure).  

Similar findings were confirmed in a subset of 22 cases with paired CSF and plasma follow-up values in the first 60 days (sensitivity/specificity: 66.7%/93.8% for slope and 66.7%/93.3% for delta in CSF, and 83.3%/87.5% for slope and 100%/68.8% for delta in plasma).

Conclusions

Conclusions. Both CSF and plasma JCV-DNA changes could predict PML outcome during the first 90 days of diagnosis, at an earlier time in plasma compared to CSF. Longitudinal JCV-DNA measurements in plasma, in addition to CSF, may provide an early new non-invasive biomarker for monitoring PML course in real-time.

Table or Figure